EUROPEAN BIOTECHNOLOGY MAGAZINE - The COVID-19 pandemic transformed RNA technologies into one of the most visible scientific breakthroughs of the decade. mRNA vaccines demonstrated unprecedented speed of development, large-scale manufacturing capability and global deployment, pushing RNA therapeutics into the public spotlight. But according to...

EU PERSPECTIVES - When it comes to cancer medicines, the EU should look beyond a purely 'Made in Europe' approach and embrace 'Made with Europe', according to Giancarlo Benelli, Head of Europe at BeOne Medicines. "Cancer does not have borders," he says, as many European patients still wait too long for innovative treatments. He argues that...

EU PERSPECTIVES - How can Europe attract more doctors, nurses and other healthcare workers — and, crucially, keep them in the profession? As staff shortages deepen across the bloc, the European Parliament has backed a plan to recruit at least one million people over the next seven years. But lawmakers face a growing dilemma: how to fill the...

EU PERSPECTIVES - The Ebola outbreak in Africa is becoming more than a public health emergency. As EU ministers meet to coordinate their response, the European Commission is presenting the crisis as evidence that Europe must invest more heavily in preparedness, vaccines and medical countermeasures before the next outbreak arrives. Read more

EU PERSPECTIVES - Brussels is willing to accept higher costs for healthcare systems to win the global biotech race. A new EU incentive would extend intellectual property rights for a handful of cutting-edge drugs, delaying cheaper biosimilars at an estimated €615 million a year. Europe is betting the trade-off will be worth it. Read more

EURACTIV - Belgian biopharma firm UCB has entered one of the most aggressive strategic expansion phases in its recent history, using acquisitions and partnerships across the United States, China and Europe to rapidly expand its biotechnology capabilities. Read more

EU PERSPECTIVES - Six years after COVID-19 upended the world, governments are still struggling to agree on how future pandemics should be handled. But the World Health Assembly also revealed a broader shift: global health policy is no longer focused only on responding to crises, but increasingly on preventing them before they spiral out of control....

EU PERSPECTIVES - The latest hantavirus outbreak is forcing Europe to confront an uncomfortable reality: vaccines or treatments against some dangerous viruses may never reach the market. Not because the science is impossible, but because developing them is not commercially attractive for pharmaceutical companies. Brussels is increasingly...

EURACTIV - Benoît van den Hove tells Euractiv that scaling biotech companies at a global level still depends on capital that Europe does not yet mobilise at sufficient scale. Read more

APM MARKET ACCESS - The European Council and the European Parliament have reached a provisional agreement on implementing tariff elements of the EU-U.S. Joint Statement, as pharmaceutical industry groups warn that continued uncertainty around transatlantic trade could disrupt drug supply chains and increase pressure on smaller innovative companies....